Lilly's fourth-quarter profit doubles, driven by diabetes and obesity treatments. Strong revenue and forecast for 2025.

Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 ...

Both have been unexpected, and upsetting, side-effects of my decision last year to become one of the thousands of women turning to the weight-loss jab Mounjaro. I've heard of other users ...

Demand has rocketed for slimming injections such as ­Ozempic and Mounjaro, known as GLP-1 receptor agonists. Researchers found people taking the jabs had lower rates of 42 ­conditions ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

The latest to join the ranks is the so-called “natural Mounjaro” drink for weight loss. Recipes vary slightly depending on which one you find, but the natural Mounjaro drink generally consists of ...